Evidence map›Paper›PMID 26740662›Full record

ArticleThe Journal of neuroscience : the official journal of the Society for Neuroscience2016

Sustained Suppression of Hyperalgesia during Latent Sensitization by μ-, δ-, and κ-opioid receptors and α2A Adrenergic Receptors: Role of Constitutive Activity.

Wendy M Walwyn, Wenling Chen, Hyeyoung Kim, Ani Minasyan, Helena S Ennes, James A McRoberts, Juan Carlos G Marvizón

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of neuroscience : the official journal of the Society for Neuroscience, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed
5.1field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 63 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Analgesia through FKBP51 inhibition at disease onset confers lasting relief from sensory and emotional chronic pain symptoms.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. HDAC6 Inhibition Reverses Cisplatin-Induced Mechanical Hypersensitivity via Tonic Delta Opioid Receptor Signaling.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2022
    Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Wendy M WalwynDepartment of Psychiatry and Biobehavioral Sciences and.
Wenling ChenDivision of Digestive Diseases, Department of Medicine, David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, California 90095, and Veteran Affairs Greater Los Angeles Healthcare System, Los Angeles, California 90073.
Hyeyoung KimDivision of Digestive Diseases, Department of Medicine, David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, California 90095, and.
Ani MinasyanDepartment of Psychiatry and Biobehavioral Sciences and.ORCID http://orcid.org/0000-0002-6370-9848
Helena S EnnesDivision of Digestive Diseases, Department of Medicine, David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, California 90095, and.
James A McRobertsDivision of Digestive Diseases, Department of Medicine, David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, California 90095, and.
Juan Carlos G MarvizónDivision of Digestive Diseases, Department of Medicine, David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, California 90095, and Veteran Affairs Greater Los Angeles Healthcare System, Los Angeles, California 90073 marvizon@g.ucla.edu.
University of California, Los Angeles · US

Funding

The Role of Striosome Neurons in Mediating Opiod RewardP50DA005010 · NIDA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI YANG, XIANGDONG WILLIAM · 1987 to 2021
$30.7M
Pilot and Feasibility ProgramP30DK041301 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ROZENGURT, JUAN ENRIQUE · 1990 to 2019
$18.0M
NEUROPEPTIDERGIC INHIBITION OF SPINAL PAIN TRANSMISSIONR01NS045954 · NINDS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI BRADLEY K. TAYLOR · 2002 to 2026
$7.4M
NMDA Receptors in Primary AfferentsR01DA033059 · NIDA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI MARVIZON, JUAN CARLOS GARCIA, MCROBERTS, JAMES A · 2012 to 2016
$1.4M
Neurotransmitter control of substance P release in the spinal cordI01RX000378 · VA · VA GREATER LOS ANGELES HEALTHCARE SYSTEM · PI MARVIZON, JUAN CARLOS GARCIA · 2012 to 2014
–
Latent Sensitization and Neuropathic PainI01RX001646 · VA · VA GREATER LOS ANGELES HEALTHCARE SYSTEM · PI MARVIZON, JUAN CARLOS GARCIA · 2016 to 2018
–
NIDA NIH HHS DA005010NIDA NIH HHS P50 DA005010NIDA NIH HHS R01 DA033059NIDA NIH HHS R01-DA033059NIDDK NIH HHS P30 DK041301NINDS NIH HHS R01 NS045954RRD VA I01 RX000378RRD VA I01 RX001646
6 · The paper itself

Abstract

Many chronic pain disorders alternate between bouts of pain and periods of remission. The latent sensitization model reproduces this in rodents by showing that the apparent recovery ("remission") from inflammatory or neuropathic pain can be reversed by opioid antagonists. Therefore, this remission represents an opioid receptor-mediated suppression of a sustained hyperalgesic state. To identify the receptors involved, we induced latent sensitization in mice and rats by injecting complete Freund's adjuvant (CFA) in the hindpaw. In WT mice, responses to mechanical stimulation returned to baseline 3 weeks after CFA. In μ-opioid receptor (MOR) knock-out (KO) mice, responses did not return to baseline but partially recovered from peak hyperalgesia. Antagonists of α2A-adrenergic and δ-opioid receptors reinstated hyperalgesia in WT mice and abolished the partial recovery from hyperalgesia in MOR KO mice. In rats, antagonists of α2A adrenergic and μ-, δ-, and κ-opioid receptors reinstated hyperalgesia during remission from CFA-induced hyperalgesia. Therefore, these four receptors suppress hyperalgesia in latent sensitization. We further demonstrated that suppression of hyperalgesia by MORs was due to their constitutive activity because of the following: (1) CFA-induced hyperalgesia was reinstated by the MOR inverse agonist naltrexone (NTX), but not by its neutral antagonist 6β-naltrexol; (2) pro-enkephalin, pro-opiomelanocortin, and pro-dynorphin KO mice showed recovery from hyperalgesia and reinstatement by NTX; (3) there was no MOR internalization during remission; (4) MORs immunoprecipitated from the spinal cord during remission had increased Ser(375) phosphorylation; and (5) electrophysiology recordings from dorsal root ganglion neurons collected during remission showed constitutive MOR inhibition of calcium channels. SIGNIFICANCE STATEMENT: Chronic pain causes extreme suffering to millions of people, but its mechanisms remain to be unraveled. Latent sensitization is a phenomenon studied in rodents that has many key features of chronic pain: it is initiated by a variety of noxious stimuli, has indefinite duration, and pain appears in episodes that can be triggered by stress. Here, we show that, during latent sensitization, there is a sustained state of pain hypersensitivity that is continuously suppressed by the activation of μ-, δ-, and κ-opioid receptors and by adrenergic α2A receptors in the spinal cord. Furthermore, we show that the activation of μ-opioid receptors is not due to the release of endogenous opioids, but rather to its ligand-independent constitutive activity.

Indexed as

Adrenergic alpha-2 Receptor AntagonistsAnimalsFreund's AdjuvantHyperalgesiaMaleMiceMice, Inbred C57BLMice, KnockoutNarcotic AntagonistsPain MeasurementRatsRats, Sprague-DawleyReceptors, Adrenergic, alpha-2Receptors, OpioidSpecies SpecificityTreatment OutcomeAdrenergic alpha-2 Receptor AntagonistsFreund's AdjuvantNarcotic AntagonistsReceptors, Adrenergic, alpha-2Receptors, Opioidadrenergic receptorconstitutive activityhyperalgesiakappa-opioid receptorlatent sensitizationmu-opioid receptor

Identifiers

PMID26740662
PMCPMC4701961
OpenAlexW2227817565

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.